|Dr. Thomas Meyer||Founder, Chairman, CEO & MD||N/A||N/A||1968|
|Mr. Hernan Levett CPA, CPA||Chief Financial Officer||N/A||N/A||1976|
|Mr. Raoul F. Dias||Gen. Counsel & Sec.||N/A||N/A||N/A|
|Colleen A. DeVries||SVP of Cogency Global Inc.||N/A||N/A||N/A|
Auris Medical Holding Ltd., a development-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear and vestibular disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 for the intranasal treatment of vertigo; and intranasal betahistine for the prevention of weight gain and drowsiness, which are side effects of various antipsychotic drugs. The company has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Zug, Switzerland.
Auris Medical Holding Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.